NovaBay Pharmaceuticals, Inc. Provides Business Update and 2013 Outlook
EMERYVILLE, Calif., Dec. 13, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today provided a business update highlighting recent accomplishments and outlook for 2013.